NASDAQ:ACCD Accolade (ACCD) Stock Forecast, Price & News $10.90 -0.82 (-7.00%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$10.85▼$11.5550-Day Range$10.90▼$15.0252-Week Range$6.83▼$17.00Volume695,132 shsAverage Volume624,960 shsMarket Capitalization$824.37 millionP/E RatioN/ADividend YieldN/APrice Target$15.59 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Accolade MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside43.1% Upside$15.59 Price TargetShort InterestHealthy4.42% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.27Based on 8 Articles This WeekInsider TradingSelling Shares$103,506 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.72) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.69 out of 5 starsBusiness Services Sector60th out of 312 stocksBusiness Services, Not Elsewhere Classified Industry20th out of 86 stocks 4.3 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.59, Accolade has a forecasted upside of 43.1% from its current price of $10.90.Amount of Analyst CoverageAccolade has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.42% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Accolade has recently decreased by 3.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private general practice doctor's diagnostic online appointments", "Private oncologist's appointments", "Private neurologist's appointments", "Private otolaryngologist's appointments", and "Private cardiologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.85. Previous Next 2.4 News and Social Media Coverage News SentimentAccolade has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Accolade this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Accolade to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,506.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions73.92% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.72) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Accolade (NASDAQ:ACCD) StockAccolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comInstitutional owners may take dramatic actions as Accolade, Inc.'s (NASDAQ:ACCD) recent 7.4% drop adds to one-year lossesSeptember 20, 2023 | finance.yahoo.comAccolade to Announce Fiscal Second Quarter 2024 Financial ResultsSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 20, 2023 | americanbankingnews.comAccolade, Inc. (NASDAQ:ACCD) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 18, 2023 | finance.yahoo.comAccolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare ExperienceSeptember 13, 2023 | finance.yahoo.comInsider Sell: Accolade Inc President Robert Cavanaugh Sells 215 SharesSeptember 9, 2023 | fool.comAccolade (NASDAQ: ACCD)September 7, 2023 | msn.comBraze, Inc. (BRZE) Reports Q2 Loss, Tops Revenue EstimatesSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 6, 2023 | finance.yahoo.comCORRECTING and REPLACING -- Accolade To Present at Upcoming Investor ConferencesSeptember 5, 2023 | finance.yahoo.comAccolade To Present at Upcoming Investor ConferencesAugust 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for AccoladeJuly 27, 2023 | finance.yahoo.comAccolade, Inc.'s (NASDAQ:ACCD) Intrinsic Value Is Potentially 91% Above Its Share PriceJuly 27, 2023 | msn.comAre Business Services Stocks Lagging Accolade (ACCD) This Year?July 27, 2023 | finance.yahoo.comAre Business Services Stocks Lagging Accolade (ACCD) This Year?July 22, 2023 | seekingalpha.comAccolade: Leveraging Tech To Deliver Accessible HealthcareJuly 20, 2023 | seekingalpha.comAccolade: Growth Reacceleration In FY25 Should Drive Valuation UpsideJuly 10, 2023 | finance.yahoo.comDespite Accolade's Pullback, Insiders Still Gained US$31kJuly 4, 2023 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Accolade (ACCD)July 2, 2023 | finance.yahoo.comAccolade, Inc. (NASDAQ:ACCD) Q1 2024 Earnings Call TranscriptJune 30, 2023 | finanznachrichten.deAccolade, Inc.: Accolade Announces Results for Fiscal First Quarter 2024June 30, 2023 | finance.yahoo.comWhy Accolade Stock Popped by Almost 7% TodayJune 30, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Accolade (ACCD)June 30, 2023 | markets.businessinsider.comAccolade's Pipeline Strength Amid Solid Demand To Propel Growth, Bullish Analyst SaysJune 30, 2023 | msn.comAccolade Rises as Losses Narrow in Q1June 30, 2023 | markets.businessinsider.comAnalyst Says Accolade's Q1 Earning, Annual Guidance Reflect Solid Performance Amid Uncertain Macroeconomic EnvironmentJune 30, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Accolade (ACCD)See More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address ACCD Company Calendar Last Earnings6/29/2023Today9/21/2023Next Earnings (Confirmed)10/04/2023Fiscal Year End2/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,370Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.59 High Stock Price Forecast$19.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+43.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-459,650,000.00 Net Margins-41.86% Pretax Margin-41.76% Return on Equity-32.34% Return on Assets-17.13% Debt Debt-to-Equity Ratio0.62 Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$363.14 million Price / Sales2.27 Cash FlowN/A Price / Cash FlowN/A Book Value$6.51 per share Price / Book1.67Miscellaneous Outstanding Shares75,630,000Free Float69,354,000Market Cap$824.37 million OptionableNot Optionable Beta1.74 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 55)Chairman & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 54)Pres Comp: $582.63kMr. Stephen H. Barnes CPA (Age 51)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSr. VP of OperationsMr. Colin McHugh (Age 44)Chief Accounting Officer Mr. Todd FriedmanSr. VP of Investor RelationsMr. Richard Eskew (Age 48)Exec. VP, Gen. Counsel, CCO & Sec. Ms. Jennifer HansonExec. VP & Chief Human Resource OfficerMr. Drew GarnerExec. VP of EngineeringDr. Shantanu Nundy M.B.A.M.D., Exec. VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsAdvantage SolutionsNASDAQ:ADVPaysafeNYSE:PSFERepayNASDAQ:RPAYConduentNASDAQ:CNDTInternational Money ExpressNASDAQ:IMXIView All CompetitorsInsiders & InstitutionsRajeev SinghSold 378 sharesTotal: $4,464.18 ($11.81/share)Robert N CavanaughSold 157 sharesTotal: $1,854.17 ($11.81/share)Stephen H BarnesSold 121 sharesTotal: $1,429.01 ($11.81/share)Rajeev SinghSold 662 sharesTotal: $8,758.26 ($13.23/share)Stephen H BarnesSold 221 sharesTotal: $2,923.83 ($13.23/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock - Frequently Asked Questions Should I buy or sell Accolade stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price forecast for 2023? 15 analysts have issued twelve-month target prices for Accolade's shares. Their ACCD share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $15.59 in the next year. This suggests a possible upside of 43.1% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2023? Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 39.9% and is now trading at $10.90. View the best growth stocks for 2023 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023. View our ACCD earnings forecast. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) released its quarterly earnings data on Thursday, June, 29th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.10. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $90.82 million. Accolade had a negative net margin of 41.86% and a negative trailing twelve-month return on equity of 32.34%. The company's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business earned ($0.62) EPS. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Accolade issued on next quarter's earnings? Accolade updated its second quarter earnings guidance on Wednesday, July, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $93.22 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. What is Accolade's stock symbol? Accolade trades on the NASDAQ under the ticker symbol "ACCD." Who are Accolade's major shareholders? Accolade's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (8.72%), Brown Advisory Inc. (8.06%), ARK Investment Management LLC (7.52%), Bellevue Group AG (5.98%), Rock Springs Capital Management LP (3.73%) and Dimensional Fund Advisors LP (2.05%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Accolade's stock price today? One share of ACCD stock can currently be purchased for approximately $10.90. How much money does Accolade make? Accolade (NASDAQ:ACCD) has a market capitalization of $824.37 million and generates $363.14 million in revenue each year. The company earns $-459,650,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. How many employees does Accolade have? The company employs 2,370 workers across the globe. How can I contact Accolade? Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com. This page (NASDAQ:ACCD) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.